Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

179.40GBp
30 Jun 2015
Change (% chg)

-- (--)
Prev Close
179.40p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
677,038
52-wk High
183.75p
52-wk Low
113.25p

VEC.L

Chart for VEC.L

About

Vectura Group plc is a respiratory product development company. The Company focuses on the development of pharmaceutical therapies for treating airways-related diseases. The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, some of which are licensed to pharmaceutical... (more)

Overall

Beta: 0.24
Market Cap(Mil.): £721.41
Shares Outstanding(Mil.): 406.20
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): 217.11 35.73 39.36
EPS (TTM): 0.01 -- --
ROI: 1.38 17.15 16.35
ROE: 1.65 18.03 17.47
Search Stocks

Vectura Group appoints AstraZeneca executive as CEO

June 24 - Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca executive James Ward-Lilley as chief executive officer effective Oct. 1.

24 Jun 2015

BRIEF-Vectura appoints James Ward-Lilley as CEO

* Announces appointment of James Ward-Lilley as CEO and executive director. James will succeed Dr Chris Blackwell who, as previously announced, leaves Vectura at end of June 2015

24 Jun 2015

BRIEF-FTSE says Spirit Pub to be deleted from 250 index, Vectura added

* Vectura Group (UK, B01D1K4) will be added to FTSE 250 index

18 Jun 2015

Vectura revenue jumps 59 pct, beats estimates

May 20 - Respiratory drugs specialist Vectura Group Plc reported a bigger-than-expected jump in full-year revenue as it raked in higher royalty payments and licensing revenue.

20 May 2015

BRIEF-Vectura Group FY revenue up 59 pct to 58 mln stg

* Revenues up 59 pct to 58 mln stg (2013/14: 36.5 mln stg) from increased royalties and milestone payments

20 May 2015

BRIEF-Vectura says to close site in Gem√ľnden, Germany

* Intention to close its site in Gem√ľnden, germany, effective by March 2016

14 Apr 2015

BRIEF-Vectura says NDAs for QVA149 and NVA237 accepted by FDA

* Acceptances trigger milestone payments to Vectura of $12.5 mln and $7.5 mln respectively Source text for Eikon: Further company coverage:

05 Mar 2015

BRIEF-Vectura says CEO to step down at the end of June

* Chris Blackwell will remain in his role until end of June 2015 and will assist board with search for his successor Source text for Eikon: Further company coverage:

03 Feb 2015

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.

06 Jan 2015

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON, Jan 6 - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.

06 Jan 2015

Earnings vs. Estimates

Search Stocks